GlassScriptPhysician profile
Joanne L Schlesinger
NPI 1518119692
$4,590.82
in general payments reported to CMS, 2019-2025
49 companies · $677 in 2025
The $677 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $1,001 · 2023: $1,866 · 2024: $848 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.19 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $358.62 | 2022-2025 | Reblozyl, Opdivo |
| Celgene Corporation | $325.65 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $321.50 | 2022-2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $298.76 | 2022-2025 | |
| Abbvie INC. | $259.22 | 2022-2025 | |
| Pfizer INC. | $225.88 | 2021-2024 | |
| Daiichi Sankyo INC. | $222.85 | 2023-2025 | Enhertu, Injectafer |
| Genentech USA, INC. | $207.42 | 2021-2024 | Rozlytrek, Tecentriq, Alecensa |
| Merck Sharp & Dohme LLC | $204.67 | 2021-2023 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $203.64 | 2023-2025 | Darzalex, Imbruvica, Carvykti |
| Alexion Pharmaceuticals, INC. | $124.77 | 2022-2024 | Ultomiris |
| Incyte Corporation | $114.03 | 2022-2023 | Monjuvi, Jakafi, Pemazyre |
| Gilead Sciences, INC. | $113.52 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $100.26 | 2022-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $99.66 | 2021-2023 | Lynparza |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $99.53 | 2023 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $89.33 | 2022-2023 | |
| Genzyme Corporation | $84.30 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $81.12 | 2021-2024 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $71.22 | 2023-2025 | Alunbrig, Ninlaro, Vpriv |
| Stemline Therapeutics INC. | $64.45 | 2023-2024 | Orserdu, Elzonris |
| Genmab U.S., INC. | $62.57 | 2023-2024 | Epkinly |
| Array Biopharma INC | $58.09 | 2022-2025 | Mektovi, Tukysa, Braftovi |
| Karyopharm Therapeutics INC. | $57.10 | 2022 | |
| Emd Serono, INC. | $56.18 | 2023 | Tepmetko, Bavencio |
| Lilly USA, LLC | $53.63 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Mirati Therapeutics, INC. | $50.10 | 2023 | Krazati |
| Amgen INC. | $48.65 | 2023 | Lumakras, Kyprolis, Prolia |
| Glaxosmithkline, LLC. | $48.40 | 2024 | Ojjaara |
| Servier Pharmaceuticals LLC | $44.96 | 2024-2025 | |
| Astellas Pharma US INC | $40.62 | 2022-2024 | Xospata |
| Beigene USA, INC. | $37.85 | 2023-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $31.58 | 2022-2023 | Tavalisse, Rezlidhia |
| Springworks Therapeutics, INC. | $29.63 | 2025 | Ogsiveo |
| Kite Pharma, INC. | $29.48 | 2025 | Yescarta |
| Taiho Oncology, INC. | $26.81 | 2023 | |
| Mylan Institutional INC. | $25.61 | 2023 | Ogivri, Fulphila |
| Pharmacosmos Therapeutics INC. | $23.81 | 2024 | Monoferric |
| Organon LLC | $21.35 | 2023 | Ontruzant |
| Blueprint Medicines Corporation | $20.68 | 2023 | Ayvakit |
| Eisai INC. | $19.82 | 2024 | |
| Boston Scientific Corporation | $19.62 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.68 | 2023 | Givlaari |
| Chiesi USA, INC. | $17.17 | 2024 | Ferriprox |
| Aveo Pharmaceuticals, INC. | $16.53 | 2025 | |
| Sobi, INC | $16.19 | 2023 | |
| Epizyme, INC. | $15.96 | 2022 | |
| Kyowa Kirin, INC. | $15.53 | 2023 | Poteligeo |
| Agios Pharmaceuticals, INC. | $14.82 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Schlesinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.